ClinicalTrials.gov
ClinicalTrials.gov Menu

Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01253460
Recruitment Status : Terminated (Accrual not met)
First Posted : December 3, 2010
Last Update Posted : April 9, 2018
Sponsor:
Collaborators:
Cyclacel Pharmaceuticals, Inc.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Terminated
  Actual Primary Completion Date : March 28, 2018
  Actual Study Completion Date : March 28, 2018